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Abstract 
Evaluation of the effects of purine C-8 substitution within a series of CDK1/2-selective O6-
cyclohexylmethylguanine derivatives, revealed that potency decreases initially with increasing size 
of the alkyl substituent. Structural analysis showed that C-8 substitution is poorly tolerated, and to 
avoid unacceptable steric interactions, these compounds adopt novel binding modes. Thus, 2-
amino-6-cyclohexylmethoxy-8-isopropyl-9H-purine adopts a 'reverse' binding mode where the 
purine backbone has flipped 180°. This provided a novel lead chemotype from which we have 
designed more potent CDK2 inhibitors using, in the first instance, quantum mechanical energy 
calculations. Introduction of an ortho-tolyl or ortho-chlorophenyl group at the purine C-8 position 
restored the potency of these ‘reverse’ binding mode inhibitors to that of the parent 2-amino-6-
cyclohexylmethoxy-9H-purine. By contrast, the corresponding 8-(2-methyl-3-sulfamoylphenyl)-
purine derivative exhibited sub-micromolar CDK2-inhibitory activity by virtue of engineered 
additional interactions with Asp86 and Lys89 in the reversed binding mode, as confirmed by X-ray 
crystallography. 
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Introduction 
Deregulation of the cell cycle is a vital motif in most, if not all, human malignancies.1,2 
Phosphorylation of pRb, the product of the retinoblastoma gene, by cyclin-dependent kinase (CDK) 
family members is required for G1 progression, and mutation of the pRb gene or abnormalities in 
the pRb signalling pathway are a common feature of cancer. For example, over-expression and/or 
mutation of CDK4 and cyclin D has been reported in various tumour types, and mutation of the 
p16INK4A gene that results in its deletion or silencing, is one of the most frequent genetic alterations 
found in human tumors.3,4 Over-expression of cyclin E and reduced levels of p27Kip1 have also been 
observed to correlate with disease progression,5,6 suggesting that deregulation at various 
checkpoints throughout the cell cycle is a key contributor to the process of tumorigenesis. As a 
result of these studies, the CDK family is considered an important target for therapeutic intervention 
in cancer and other diseases, and a wide range of ATP-competitive inhibitors have been 
developed.7-9 However, although a number of small-molecule CDK inhibitors have progressed to 
clinical trials (e.g. 1-4), a kinase-specific CDK inhibitor has yet to be approved by the FDA for 
clinical use.7,10,11 
 
Initial enthusiasm for CDK2 as a cancer therapeutic target was tempered by subsequent studies 
demonstrating that CDK2 siRNA or antisense constructs failed to induce cell cycle arrest in a 
number of human tumor cell lines,12 and that CDK2 knockout mice are viable.13,14 However, more 
recent evidence suggests that CDK2 inhibition may elicit antitumor activity in a subset of tumors 
with defined genetic characteristics. For example, CDK2 knockdown or treatment with roscovitine 
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(1) is selectively toxic to MYCN-amplified neuroblastoma cells compared with their non-amplified 
counterparts.15 Compelling evidence to support a therapeutic role for pharmacological CDK2 
inhibition in cancer treatment has also been adduced very recently, employing a chemical genetic 
approach.16 Thus, a comparison of selective small-molecule CDK2 inhibition with that imposed by 
siRNA knockdown in normal and tumor cells highlighted important differences between these 
approaches, with pharmacological inhibition resulting in growth inhibition of a panel of human 
cancer cells transformed with various oncogenes. A recent study demonstrating that a combination 
of phosphatidylinositol-3-kinase (PI3-K) and CDK2 inhibitors induced apoptosis in malignant 
glioma xenografts via a synthetic-lethal interaction, also highlights the potential of CDK2-selective 
inhibitors.17 
 
We have previously reported the structure-based design of a series of potent CDK2-selective 
inhibitors derived from the lead compound O6-cyclohexylmethylguanine (NU2058, 5; CDK2 IC50 = 
16.0 M), as exemplified by 6 and 7 (CDK2; IC50 = 1.0 M and 5.0 nM, respectively).18-22 The X-
ray crystal structure of 5 in complex with monomeric unphosphorylated CDK2, revealed that the 
purine heterocycle binds within the ATP-binding pocket in a different orientation from that 
previously reported for ATP, isopentenyladenine, and the prototypic purine CDK inhibitor 
olomoucine (8).23 The 9-NH group of 5 forms a hydrogen-bond with the backbone carbonyl of 
Glu81, while the purine N-3 and 2-amino group make hydrogen-bonds with the backbone nitrogen 
NH and carbonyl of Leu83, respectively. In this orientation, the C-8 position of 5 is directed 
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towards the side-chain of Phe80 in the gatekeeper pocket (Figure 1). A number of purine-based 
CDK inhibitors derive potency from interacting with this residue; for example, purvalanol B (9)24 
and H717 (10)25 both pack hydrophobic aliphatic substituents against the Phe80 side chain. In 
contrast, a series of bisanilinopyrimidines (e.g. 11) abut polar and polarisable groups against the 
phenyl ring of Phe80, and the observed gain in potency for this compound series is attributed to 
induced dipole-dipole interactions.26, 27 
A B 
 
 
Figure 1. (A) Purine 5 bound to the CDK2 ATP-binding domain. The kinase is presented in dark 
green in ribbon representation, and selected CDK2 residues and 5 are drawn in ball and stick mode. 
Carbon atoms of 5 are coloured light green and hydrogen bonds are denoted by dashed lines. (B) 
Schematic representation of the bonds made between CDK2 and 5. Hydrogen bonds are drawn as 
arrows. The double-headed arrow denotes the distance between the purine C8 atom and the side-
chain of Phe80. 
 
The close proximity of the imidazole ring of 5 to the Phe80 side-chain observed in the structure 
of the inhibitor in complex with CDK2, implied that substitution at the purine C-8 position would 
not be tolerated. To confirm this prediction, and as part of SAR studies for this chemotype, three 
derivatives of 5 bearing alkyl groups at the 8-position (24-26) were initially synthesised, and the 
crystal structure of the 8-isopropylpurine (26) bound to CDK2 was determined. Purine 26 was 
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found to adopt a different binding orientation from that observed for 5 within the ATP-binding 
domain, offering the opportunity to exploit alternative inhibitor-protein interactions through 
judicious structural modifications to the parent purine 5. In this paper, we describe the elaboration 
of this binding mode through iterative compound synthesis, molecular modelling and X-ray 
crystallographic analysis of CDK2/cyclin A/inhibitor complexes. These studies have achieved 
improved CDK2-inhibitory activity by virtue of an engineered additional CDK2-inhibitor 
interaction. 
Chemistry 
The initial target 8-substituted O6-cyclohexylmethylguanine derivatives (24-29, 32) were readily 
synthesised following the procedures illustrated in Scheme 1. Thus, acylation of the 6-amino group 
of 2,6-diamino-4-cyclohexylmethoxy-5-nitrosopyrimidine (17)18 afforded the 6-
acylaminopyrimidines (18-23), which were readily cyclised to the required purines (24-29) in good 
overall yields on reduction of the 5-nitroso substituent by catalytic hydrogenation. Efforts to prepare 
the 8-trifluoromethylpurine 32 by this approach were unsuccessful, with 17 proving refractory to 
acylation with TFA-anhydride or ethyl trifluoroacetate. However, direct acylation of 
triaminopyrimidine 30 with TFA gave the required trifluoroacetylaminopyrimidine 31, which 
slowly cyclised to the requisite purine 32 on prolonged heating in pyridine-DMAP. 
Scheme 1a 
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a Reagents and conditions: (i) 18-21, (RCO)2O, DMF, 80 °C, 22 and 23, ArCOCl, pyridine, 
DMAP, 25 °C; (ii) H2, Pd/C, AcOH, THF, 20 °C; (iii) TFA, reflux; (iv) DMAP, pyridine, reflux. 
The preparation of O6-cyclohexylmethylguanine derivatives bearing substituted aryl groups at 
the purine 8-position required palladium-catalyzed cross-coupling methodology (Scheme 2). Direct 
8-arylation of the N9-benzylpurine 33 with the appropriate aryl bromides, employing CuI-Pd(OAc)2 
under microwave irradiation, furnished benzyl-protected intermediates 34 and 35, and subsequent 
conversion into the requisite phenol 36 and benzoic acid 37 was achieved in moderate yield by 
catalytic hydrogenation under acidic conditions. An alternative approach utilized the 8-bromopurine 
39, readily synthesized by treatment of the t-BOC-protected purine derivative 38 with N-
bromosuccinimide, which concomitantly removed the protecting group, or via direct bromination of 
5 with pyridinium tribromide. Suzuki-Miyaura cross coupling of 39 with the appropriate boronate 
derivatives (15, 16), prepared from the corresponding aryl halides (12, 14) by standard methods, or 
generated in situ from 13, gave the PMB-protected compounds (40-42), which were smoothly 
deprotected to the required 8-substituted purines 43-45 on treatment with TFA. 
Scheme 2a 
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a Reagents and conditions: (i) (a) TsCl, pyridine, 0-25 °C, (b) PMB-Cl, DMAP, 25 °C; (ii) 
bis(pinacolato)diboron, PdCl2[[(C4H9)2PC5H4]2Fe], [(C4H9)2PC5H4]2Fe, KOAc, dioxane, MW 150 
°C; (iii) PMB-Cl, NaH, DMF, 80 °C (13) 25 °C (14);  (iv) BnBr, K2CO3, DMF, 25 °C; (v) 
Pd(OAc)2, CuI, CsCO3, DMF, MW 200 °C; (vi) H2, Pd/C, AcOH, aq. HCl, 20 °C; (vii) (tBuO)2CO, 
K2CO3, DMF, 20 °C; (viii) pyridinium tribromide, DCM, 70 °C; (ix) NBS, MeCN, 20 °C; (x) 
Appropriate arylboronate, PdCl2[[(C4H9)2PC5H4]2Fe], Cs2CO3, aq. dioxane, 110 °C; (xi) TFA, 20-
110 °C. 
Results and Discussion 
The inhibitory activity of the purine derivatives against CDK1 and CDK2 is shown in Table 1. Our 
previous studies with O6-alkylguanines were founded on the benchmark O6-alkylguanine NU2058 
(5) and culminated in the identification of NU6102 (7), a highly selective CDK2 inhibitor that was 
designed by a structure-based inhibitor design approach. The markedly increased potency of 7 
(CDK2; IC50 = 5 nM) compared with 5 (CDK2; IC50 = 16 M) is attributed to additional favourable 
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interactions between the sulfonamide function of 7 and the specificity surface of the ATP-binding 
domain of the kinase.20 The primary sulfonamide function of 7 also provided an opportunity to 
develop a water-soluble prodrug, by virtue of N-acetylation and formulation as the potassium salt, 
and in vivo studies are in progress.28 With a view to further delineating SARs for this interesting 
class of kinase inhibitor, the effect of substitution at the C-8 position of 5 was investigated. 
Table 1. Inhibition of CDK1 and CDK2 by C8-substituted O6-cyclohexylmethylguanines 
 
 Number Structure R R’ 
IC50 (M)a or % inhibition 
 CDK2/Cyclin A CDK1/Cyclin B 
 5 A H - 16 ± 2.0b 26 ± 3.5 
 6 B H - 0.97 ± 0.03 10.0 ± 1.6 
 7 B SO2NH2 - 0.005 ± 0.001 0.25 ± 0.05 
 24 A Me - 44.7 ± 3.2 7%, 11%c 
 25 A Et - 30.3 ± 1.5 77.5 
 26 A i-Pr - 27.7 ± 3.2 92.3 ± 4.3 
 27 C H H 10%c 35%c 
 28 C Cl H 17 ± 1.8 > 100 
 29 C Me H 18.2 ± 4.3 93.6d 
 32 A CF3 - 49 ± 2.6%
e > 100 
 36 C Me OH 23.5 ± 4.8 > 100 
 37 C Me CO2H > 100 > 100 
 43 C Me CONH2 39.8 ± 13.9 62%
d 
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 44 C H SO2NH2 8.7 ± 3.4 > 100 
 45 C Me SO2NH2 0.51 ± 0.05 2.8
d 
aIC50 values determined as described in reference 20. 
bStandard deviations obtained from three 
separate experiments. cActivity determined at 10 M owing to limiting solubility. dSingle 
determination. eActivity measured at 100 M. 
 
The crystal structure of 5 bound to CDK2/cyclin A indicated that 8-substitution would not be 
well tolerated, as a result of a steric clash between the C-8 moiety and the side-chain of Phe80 (r C8-
F80C = 3.7Å in the CDK2/5 structure).
20 This observation appeared to be confirmed by the CDK2-
inhibitory activity of the three initial derivatives, which showed a modest decrease in potency 
compared with 5 on addition of a methyl (24), ethyl, (25) or isopropyl (26) group at the purine 8-
position (IC50 values of 45, 30, and 28 M, respectively), albeit that 25 and 26 were essentially 
equipotent with 24 despite steric differences (Table 1). Where measurable, activity against CDK1 
compared with CDK2 also generally tracked that observed for 5, with 25 and 26 proving some 2-3 
times less potent against CDK1. Notably, a dramatic reduction in potency against both kinases was 
observed upon introduction of the bulky C-8 phenyl group, although a precise determination of the 
activity of 27 was limited by very poor aqueous solubility. 
Crystal structure analysis - To establish the binding mode of this inhibitor series within the ATP 
pocket, X-ray crystallographic analysis of the 8-isopropyl- and 8-trifluoromethyl-purines (26 and 
32) in complex with CDK2 was undertaken, following crystal soaking with each inhibitor. 
Interestingly, 26 was found to adopt a novel orientation within the ATP-binding site distinct from 
that observed for the parent CDK2 inhibitor 5 (Figure 2). By comparison with the ‘conventional’ 
binding mode of 5 (Figure 1), the new orientation adopted by 26 can be described by a 180 rotation 
of the purine ring about a vector coincident with the C-6 to N-3 bond. In this orientation C-8 of 26 
is directed towards the ‘selectivity surface’ of the kinase,20, 29 with the purine 2-amino group being 
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projected towards Phe80. Thus, both 5 and 26 form a conserved triplet of hydrogen bonds with the 
CDK2 hinge region, and the O6-cyclohexylmethyl substituent is retained in the ATP ribose-binding 
pocket. In both cases, the conformation and location of the O6-cyclohexylmethyl group is analogous 
to that previously observed for the structure of 7 bound to CDK2/cyclin A.20 (Supplementary Figure 
S1). 
 
A 
 
B 
Figure 2. (A) Stereoview of 26 in complex with CDK2. The kinase is presented in dark green in 
ribbon representation, and selected CDK2 residues and 26 are drawn in ball and stick mode. Carbon 
atoms of 26 are coloured light green and hydrogen bonds are denoted by dashed lines.  Water 
molecules are drawn as red spheres. (B) Schematic representation of the bonds made between 
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CDK2 and 26. Hydrogen bonds are drawn as arrows. The double-headed arrow denotes the distance 
between the purine C2 substituent and the side-chain of Phe80. 
Additional interactions of 26 with the glycine-rich loop of CDK2 contribute to stabilisation of 
the activation segment, as previously observed for the structure of 5 bound to CDK2.18 These 
interactions are predominantly lipophilic in nature, arising between the O6-cyclohexyl ring of 5 and 
26 and a hydrophobic patch on the glycine loop contributed by the side chain of residue Val18 and 
the peptide backbone around residue Gly11. The binding conformation adopted by 26 has not been 
reported previously, despite extensive structural analyses of various substituted purine-based CDK 
ATP-competitive ligands.18-20, 22-24, 30,31 
To assess whether smaller C-8 substituents would also promote this 'reverse' binding mode, the 
8-trifluoromethylpurine 32 was co-crystallised with CDK2/cyclin A phosphorylated on CDK2 
Thr160 (CDK2/cyclin A). Previous comparative crystallographic studies of inhibitor binding to 
CDK2 and to CDK2/cyclin A have shown that the interactions made between inhibitors within this 
series, and the two alternative forms of CDK2 within the adenine binding pocket, are conserved. 
Surprisingly, 32 did not share the same binding mode as 26, but rather adopted another that is 
reminiscent of, but distinct from, that of 5 (Figure 3). In contrast to the 8-isopropyl group of 26, the 
8-trifluoromethyl substituent of 32 was better accommodated, although this group is regarded as 
having a similar size to isopropyl.32 The purine of 32 was found to bind in a near identical 
orientation to that of 5, albeit less deeply within the CDK2 ATP-binding pocket. As a consequence, 
both the structure of the glycine-rich loop and the nature of the hydrogen bond interactions between 
32 and the residues within the CDK2 hinge are modified. Most notably, the characteristic hydrogen 
bond interaction between the purine 9-NH and the backbone carbonyl moiety of Glu81 observed for 
5 and 7, was absent with 32. N-2 is positioned to enable hydrogen bonding with the carbonyl group 
of Leu83 or, for this inhibitor series, to form a novel interaction with the backbone carbonyl of 
His84. The 9-NH of 32 forms two indirect hydrogen bonds with CDK2 via a water molecule, which 
is also engaged in a polar contact with one of the fluorine atoms of the C-8 trifluoromethyl group 
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that is packed against the Phe80 aromatic ring (r (CF3-aromF80) = 4.2 Å). A second fluorine atom 
mediates a network of polar contacts with two water molecules that in turn interact with the side 
chains of Glu51 and Lys33, and the amide group of Asp145.  
 
A 
 
B 
Figure 3. (A) Stereoview of 32 in complex with CDK2/cyclin A. The kinase is presented in dark 
green in ribbon representation, with selected CDK2 residues and 32 drawn in ball and stick mode. 
Carbon atoms of 32 are coloured light green and hydrogen bonds are denoted by dashed lines. 
Water molecules are drawn as red spheres. (B) Schematic representation of the bonds made 
between CDK2 and 32. Hydrogen bonds and polar interactions are drawn as arrows. The double-
headed arrow denotes a potential hydrophobic interaction between the purine C8 substituent and the 
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side-chain of Phe80.  
 
The CDK-inhibitory activity (Table 1) of the C-8 substituted purines (24-27, 32) was reassessed 
in light of the structural biology results described above. The changes in potency observed against 
both CDK1 and CDK2 that accompany C-8 alkyl substitution, compared with the parent purine 5, 
can be modelled as occurring in two phases as the size of the alkyl substituent increases. Firstly, the 
initial decrease in potency is consistent with the formation of sub-optimal interactions imposed to 
accommodate small alkyl groups such as methyl (24) at the purine C8 position. As illustrated by the 
structure of 32 in complex with CDK2/cyclin A (Figure 3), the inhibitor is forced away from Phe80 
and, consequently, the requisite triplet of hydrogen bonds with the hinge cannot be maintained. 
Further small adjustments of the ATP site residues are also necessary to accommodate the inhibitor, 
and taken together, these changes lead to a decrease in binding affinity compared with 5 as reflected 
by CDK1/CDK2 inhibitory activity in the 100 M range for 32. Increasing the size of the C-8 
substituent further results in an unacceptable steric clash with Phe80, and the inhibitor is forced to 
adopt an alternative binding mode where the C-8 group faces the selectivity surface, as observed 
with 26 (Figure 2). 
Replicating the N-2 aryl group interactions of 6 and 7 with CDK2 for C-8 substituted purines 
The unique binding orientation adopted by the 8-isopropylpurine (26) offered an opportunity to 
design novel CDK2 inhibitors based on the 6-alkoxypurine template. Accordingly, we sought to 
exploit this finding by applying the structure-aided design principles employed previously for the 
optimisation of the 2-arylaminopurines 6 and 7,20 for the identification of more potent derivatives of 
26. A key feature of the binding of 6 and 7 to CDK2, is the packing of the N-2 aryl ring against the 
CDK2 surface to form a  stacking interaction with the peptide backbone between Gln85 and 
Asp86.20 Notably, the aryl ring appears to have a low barrier to rotation about the N-2 to C-1’ bond, 
as demonstrated by the different purine-aryl interplane torsion angles of these and other 
derivatives.20,22 
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A structural superposition of 7 and 26 in complex with CDK2 and CDK2/cyclin A,20 
respectively, (Supplementary Figure S1) indicated that to replicate the aryl-backbone interactions 
made between 7 and CDK2, the aryl ring would need to be attached directly to the C-8 position, a 
compound that is most closely modelled in this series by the 8-phenylpurine 27. However, the weak 
CDK2-inhibitory activity of 27 suggested that if, as predicted, the compound binds to CDK2 in the 
reverse binding mode, the requisite additional interactions are not arising between the 8-phenyl ring 
and the kinase. One possible explanation for this observation is that the purine and phenyl rings of 
27 are essentially co-planar as a consequence of a favourable interaction of their -systems, which 
would preclude the conformation necessary to facilitate an optimal interaction between the 8-phenyl 
ring and CDK2. Indeed, evidence in support of this is provided by the crystal structure of the 
aloisine derivative RP90 (6-phenyl[5H]pyrrolo[2,3-b]pyrazine) in complex with CDK2, where the 
pyrrole and 6-phenyl rings are found to adopt a coplanar conformation.33 
With a view to optimising the interaction of the 8-phenyl ring of 27 with the backbone of the 
ATP-binding domain of CDK2, the possibility of imposing a favourable conformational twist 
between the imidazole and phenyl rings, by virtue of ortho-substitution on the 8-phenyl ring, was 
considered. To this end, quantum mechanical calculations were employed to elucidate the 
conformation-energy profiles for nine derivatives of 27, to establish whether a non-coplanar 
conformation was energetically favourable, and to identify substituents with the potential to confer 
a non-planar arrangement between the two ring systems. The ideal ortho-substituent on the 8-
phenyl ring of 27 would induce an inter-plane twist of approximately 40º, with relatively free 
rotation arising about the optimum conformation of ± 20º. This latter aspect would allow for 
optimisation of aryl ring packing against the kinase.  Such a twist was predicted to be tolerated 
based on literature evidence, where relatively large variations of torsion angles between non-
conjugated ring systems have been observed for a number of purine-based inhibitors.20, 22, 24  
Quantum mechanical calculations on model compounds derived from 27 
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A simplified model of 27 was used to investigate the possibility of inducing a phenyl-purine twist 
with C-8 phenyl ortho-substituents. As a first approximation, it was assumed that the O6-
cyclohexylmethoxy substituent of 27 would have little effect on the phenyl-purine twist angle, and 
this group was not included in the calculations. Nine model compounds (A-I) encompassing 
combinations of fluoro, chloro and methyl substituents were investigated in comparison with 27. 
Each model was constructed and energy minimised, with the purine and aryl rings constrained to a 
co-planar orientation. A rigid potential energy scan was then performed at a range of inter-planar 
angles between the two co-planar conformations (A full description of the results of this analysis for 
each compound can be found in the Supplementary Results and Supplementary Figure S2). 
The ortho-fluorophenylpurine (A) (Figure 4) was found to have both the desired characteristics 
of inducing an inter-plane twist of approximately 40º, and allowing relatively free rotation about 
this optimum conformation. However, A possesses a significantly more stable conformation at 
180º, presumably due to an intramolecular hydrogen bond. The 2-chlorophenyl derivative B has 
minima at approximately 40º and 140º that would, potentially, allow the formation of favourable 
aryl-backbone packing interactions. The 40º conformation is in a relatively shallow energy well, 
indicating some degree of rotation between the two ring systems. However, the more stable, and 
therefore preferred, conformation at 140º has a relatively steep energy well, implying a more 
restricted rotational freedom. By contrast, the ortho-methylphenylpurine C has a global minimum at 
around 40 in a relatively flat energy well. The ortho-disubstituted C8-phenylpurines E, F, H and I 
all show potential to form the required conformation, especially the 8-(2-chloro-6-
methylphenyl)purine (I), which has a minimum in a relatively flat energy well at ~ 50. 
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27 A 
  
B C 
  
 
Figure 4. Chemical structures of 27 and modelled ortho-substituted 8-arylpurines (A-I), together 
with conformation-energy profiles of 27 and three representative model compounds. 
 
To assess the validity of the modelling studies, the ortho-chlorophenyl and ortho-tolyl 
derivatives B and C were synthesised (28 and 29) and evaluated for CDK-inhibitory activity, with 
both compounds exhibiting potency comparable with the parent 2-amino-6-cyclohexylmethylpurine 
5 (Table 1). Interestingly, 28 and 29 were essentially inactive against CDK1 (IC50 values of > 100 
M and 94 M, respectively), although the poor aqueous solubility of 27 militated against a direct 
comparison with 28 and 29. The crystal structure of 29 in complex with CDK2/cyclin A was 
determined. As anticipated from the analysis of 26, the ortho-tolylpurine 29 binds in the same 
reverse binding mode and makes an identical triplet of hydrogen bonds with Glu81 and Leu83 
(Figure 5A). However, the interaction with Lys33 is not maintained, as the residue adopts a 
conformation in which the side chain is directed away from the inhibitor. The o-tolyl group of 29 is 
in the same orientation as the isopropyl group of 26, and projects towards the selectivity surface of 
0
5
10
15
20
25
30
0 60 120 180
R
e
la
ti
v
e
 E
n
e
rg
y
 (
k
J
/m
o
l)
Torsion Angle (degrees)
0
5
10
15
20
25
30
35
40
0 60 120 180
R
e
la
ti
v
e
 E
n
e
rg
y
 (
k
J
/m
o
l)
Torsion Angle (degrees)
0
5
10
15
20
25
30
35
40
0 60 120 180
R
e
la
ti
v
e
 E
n
e
rg
y
 (
k
J
/m
o
l)
Torsion Angle (degrees)
0
10
20
30
40
50
60
70
80
90
0 60 120 180
R
e
la
ti
v
e
 E
n
e
rg
y
 (
k
J
/m
o
l)
Torsion Angle (degrees)
 18 
the ATP pocket such that the C-8 atoms of compounds 26 and 29 almost coincide with the C-17 
atom of 7 (first carbon atom of the 2-arylamino group, Figure 5B). 
 
A 
 
B 
 
Figure 5. (A) Binding of 29 to CDK2/cyclin A. (B) Comparative binding of 7 and 29. A. CDK2 is 
shown in dark green. Selected residues from the CDK2 ATP binding pocket and 29 are shown as 
ball-and-stick representation and coloured dark green and light green, respectively. Water 
molecules in the vicinity of the inhibitor are included as red spheres. B. The inhibitors and selected 
residues within the CDK2 ATP binding site are shown in ball-and-stick representation. Carbon 
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atoms of CDK2 residues from 7 and 29 complex structures are coloured grey and dark green, 
respectively. Purine 7 is shown in coral and 29 in light green. 
 
Importantly, the structure of 29 bound to CDK2/cyclin A supported the results of the quantum 
mechanical calculations. The o-tolyl group on the 8-aryl ring of the purine induces an inter-ring 
twist of approximately 38° which is close to the predicted value of ~ 40°. This value is also similar 
to the inhibitor inter-planar ring tilts observed for the CDK2/cyclin A/6 and CDK2/cyclin A/7 
structures (50° and ~34°, respectively),20 suggesting that an equivalent disposition of two ring 
systems can be accommodated in either binding mode. The introduction of an ortho-methyl (or 
ortho-chloro) substituent onto the C-8 phenyl ring of 27 restores the potency of the compounds that 
adopt this altered binding mode to that of 5, the benchmark 6-alkoxypurine CDK2 inhibitor in the 
series (Table 1). However, there remained a 20-fold difference in potency between 29 (CDK2; IC50 
= 18.2 M), and the 2-phenylaminopurine derivative 6 (CDK2; IC50 = 1.0 M) that does not adopt 
the alternative binding mode. The lower potency of 29 likely results from misalignment of the 
purine, resulting in weakened hydrogen bond interactions with the CDK2 backbone in the hinge 
region. A concomitant shift of the purine ring out of the cleft will also result in sub-optimal packing 
of the C-8 phenyl ring against the peptide backbone at residues Gln85 and Asp86. 
Our previous studies with other purine- and pyrimidine-based CDK inhibitor series suggested the 
possibility of exploiting sequence differences between kinases on the 'selectivity surface,' through 
further elaboration of the 8-aryl ring of 29. For example, a number of inhibitor series probe both the 
conserved aspartate residue (Asp86 in CDK2) and the sequence differences that exist between 
CDKs at the residue equivalent to CDK2 Lys89 (Thr102 and Val100 in CDK4 and CDK7, 
respectively), to derive considerable gains in potency and selectivity.20,24,26,34,35 The potent CDK2 
inhibitor 7 evolved from 6 by the rational introduction of a sulfonamide group at the 4-position of 
the 2-phenylamino ring.20 The resultant 200-fold increase in potency, is attributable, at least in part, 
to optimal H-bond interactions arising between the sulfonamide moiety and the backbone amide 
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and side-chain of Asp86. In an effort to emulate these interactions in the context of the reversed 
binding mode, compound 29 was initially further substituted with hydroxyl (36) and carboxylate 
(37) groups at the meta-position on the C-8 aryl ring. However, these substitutions did not lead to a 
significant increase in potency, and while 36 (CDK2; IC50 = 28 M) retained activity approaching 
that of 29 (CDK2; IC50 = 18.2 M), the carboxylic acid derivative 37 was essentially devoid of 
activity against both CDK1 and CDK2 (IC50 > 100 M). Determination of the structures of 
compounds 36 and 37 bound to CDK2/cyclin A revealed the molecular details of the inhibitor 
binding modes (Supplementary Figure S3).  
 
  
A B 
Figure 6. Crystal Structures of (A) 44 and (B) 45 bound to CDK2/cyclin A. CDK2 is shown in 
green, with selected residues from the ATP-binding pocket shown in ball and stick mode. 44 and 45 
are also drawn in ball-and-stick representation with carbon atoms coloured light green. 
 
The disappointing activity of 36 and 37 prompted the introduction of meta-substituents on the 8-
aryl ring having both donor and acceptor properties, with a view to recapitulating the interactions 
with Asp86 observed for 7. Although the potency of the 3-carboxamido derivative 43 (CDK2; IC50 
= 41/53 M) suggested sub-optimal binding, the introduction of a 3-sulfonamide group (45) 
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conferred sub-micromolar CDK2-inhibitory activity (IC50 = 0.51 ± 0.05 M). Thus, 45 proved 
approximately 50-fold more potent than 26, and exhibited activity comparable with the 2-
phenylamino purine 6. Interestingly, the 8-arylpurine 44, which differs from 45 only in lacking the 
ortho-methyl group, was some 17-fold less potent (CDK2; IC = 8.7 ± 3.4 M), supportive of the 
role of the ortho-methyl function in imposing the desired conformational twist of the 8-aryl ring of 
the purine. 
The predicted binding modes of 44 and 45 were confirmed by determination of the structures of 
these purines bound to CDK2/cyclin A. Both inhibitors adopt the reverse binding mode, and, as 
predicted, the sulfonamide substituent makes hydrogen bonds to Asp86 and Lys89 (Figure 6). The 
presence of the 2-methyl group on the C-8 aryl ring of 45 imposes the requisite rotation of the entire 
group, and also precludes a steric clash between the methyl moiety and the N7 position. This 
rotation also results in a slight decrease in the distance between the sulfonamide substituent and 
Asp86 and Lys89 that may contribute to the observed increases in potency. The hydrogen bonds 
between the purine ring of 45 and the CDK2 backbone within the hinge sequence are maintained, 
but again a water molecule mediates an indirect network of interactions between N9 and the side 
chains of Lys33 and Glu81. 
Conclusion 
In the current study, the effect of substitutions at the C-8 position within a series of O6-
cyclohexylmethylguanines, on their ability to inhibit CDK2, has been evaluated.  The introduction 
of alkyl groups was poorly tolerated leading to decreases in potency, the origins of which were 
elucidated by crystallographic analysis of selected inhibitors bound to CDK2/cyclin A. The crystal 
structures of compounds 26 and 32 bound to CDK2/cyclin A revealed that they adopt novel binding 
modes within the CDK2 ATP-binding site. An increase in the size of the C-8 alkyl group from 
methyl to isopropyl induced a rotation of the binding mode so that the C-8 substituent was 
positioned to face the CDK2 specificity surface. Quantum mechanical calculations were employed 
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to identify 29, a compound that adopts the novel, reverse binding mode and is equipotent with the 
parent purine 5 against CDK2. 
Initial further elaboration of 29 by meta-substitution to exploit potential interactions with Asp86 
failed to increase potency. Structure determination of compounds 36 and 37 bound to CDK2/cyclin 
A revealed that these compounds occupy a similar position to compound 29 within the CDK2 ATP-
binding cleft. However, despite interacting with the same region as the sulfonamide group of 7, the 
hydroxyl and carboxylate substituents of 36 and 37, respectively, are not orientated to reproduce the 
favourable interactions observed in the structure of 7. However, in derivative 45 a sulfonamide 
substituent at the meta-position of the C-8 arylpurine, in tandem with an ortho-methyl group, 
maintained the reversed binding mode and also emulated the interactions made by 7, leading to the 
predicted increases in potency. Unfortunately, the relatively modest potency of 45 compared with 
the parent 2-arylamino-6-alkoxypurine CDK2 inhibitor 7, combined with only limited opportunities 
for further elaboration, militate against further optimisation of this series. 
 Small-molecule CDK inhibitors have enjoyed a resurgence of interest, as evidenced by a very 
recent review of the patent literature,36 and clinical studies with the CDK4/6 inhibitor palbociclib 
(PD-0332991) are at an advanced stage.37 These clinical studies are underpinned by a greater 
appreciation of the importance of CDK activity to normal cells, and the more careful selection of 
patient populations to ensure that effective therapeutic windows can be achieved. Previous 
experience has highlighted the importance of achieving selectivity for the target CDK over other 
family members, and the availability of crystal structures for the majority of the CDKs to guide 
inhibitor design, has proven invaluable. In this paper, we have demonstrated the application of 
molecular modelling and structure-based design for the exploitation of an unorthodox binding 
orientation of a purine-based CDK2 inhibitor. The results of the study contribute to a further 
understanding of the possible interactions of this inhibitor class with the ATP-binding domain of 
CDK2, and will be of value both in the design of more potent CDK2 inhibitors and for abrogating 
CDK2-inhibitory activity where this is required. 
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Experimental Section 
General Synthetic Procedures 
Reagents were purchased from fine chemicals vendors, and used as received unless otherwise 
stated. Solvents were purified and stored according to standard procedures. Petrol refers to that 
fraction in the boiling range 40-60 °C. THF refers to anhydrous tetrahydrofuran, either by 
distillation from sodium benzophenone, or from commercial sources. Melting points were obtained 
on a Stuart Scientific SMP3 apparatus and are uncorrected. Thin layer chromatography was 
performed using silica gel plates (Kieselgel 60F254; 0.2 mm), and visualised with UV light or 
potassium permanganate. Chromatography was conducted under medium pressure in glass columns 
or using a Biotage SP4 instrument in prepacked columns (FLASH+ Silica columns [40-63 µm, 
60Å]). Semi-prep HPLC was conducted with Varian ProStar HPLC system equipped with 2 ProStar 
210 solvent delivery modules, a ProStar 320 UV-Vis detector, a ProStar 701 fraction collector and 
controlled by Varian Star Chromatography Workstation. Proton (1H) and carbon (13C) nuclear 
magnetic resonance (NMR) spectra were recorded on a Bruker Spectrospin AC 300E (1H at 300 
MHz, 13C at 75 MHz), a Jeol JNM-LA500 spectrometer (1H at 500 MHz, 13C at 125 MHz), or a 
Bruker Avance II 500 (1H at 500 MHz, 13C at 125 MHz). Chemical shifts () are reported in parts 
per million (ppm) downfield from tetramethylsilane (TMS), using known solvent peaks as internal 
standards.  Coupling constants (J) are reported in hertz (Hz). 
IR spectra were recorded on a Bio-Rad FTS 3000MX diamond ATR. Liquid Chromatography-Mass 
Spectrometry (LCMS) was carried out on a Micromass Platform instrument operating in positive 
and negative ion electrospray mode, employing a 50 x 4.6 mm C18 column (Waters Symmetry or 
Waters Atlantis) 5 or 12 min gradient elution with 0.05% formic acid in methanol (10-90%). All 
compounds gave ≥95% purity by 1H NMR, HPLC or LCMS, unless stated otherwise. Elemental 
analyses were performed by The School of Pharmacy, Analytical Facility, University of London, 
WC1N 1AX. Accurate masses were measured using a Finnigan MAR 95 XP or a Finnigan MAR 
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900 XLT at the EPSRC National Mass Spectrometry Service Centre (Chemistry Department, 
University of Wales, Swansea, Wales, SA2 8PP). 
3-Bromo-N-(4-methoxybenzyl)-2-methylbenzamide (12). p-Toluenesulfonyl chloride (1.06 g, 
5.58 mmol) was added dropwise to a stirred solution of 3-bromo-2-methylbenzoic acid (1.0 g, 4.65 
mmol) in anhydrous pyridine (5 mL) at 0 °C, and the mixture was allowed to warm to room 
temperature with stirring over 72 h. The solvent was removed in vacuo and the residue was 
redissolved in EtOAc (20 ml), washed sequentially with aqueous HCl solution (0.1 M, 20 mL) and 
brine (2 x 20 mL), dried (MgSO4) and concentrated under reduced pressure to give 3-bromo-2-
methylbenzoic 4-methylbenzenesulfonic anhydride as a white solid (1.72 g, 100%), which was used 
directly for the next reaction. To a solution of the tosylate ester (0.46 g, 1.24 mmol) in DCM (5 mL) 
was added DMAP (15 mg, 0.12 mmol), and the mixture was stirred for 15 min at room temperature, 
prior to addition of 4-methoxybenzylamine (0.8 mL, 6.3 mmol). After stirring for a further 30 min, 
DCM (10 mL) was added, and the reaction mixture was washed sequentially with aqueous HCl 
solution (0.1 M, 20 mL) and brine (2 x 20 mL), dried (MgSO4) and the organic fraction was 
concentrated under reduced pressure. Purification by chromatography on silica, employing a 
gradient elution of Petrol:EtOAc (9:1) to Petrol:EtOAc (1:1), gave the title compound as a white 
powder (0.41 g, 100%); mp 121-122 °C; IR 3248, 1612, 1513 cm-1; 1H NMR (CDCl3, 500 MHz)  
2.44 (0.74H, s, Ar-CH3), 2.47 (2.26H, s, Ar-CH3), 3.78 (0.74H, s, OCH3), 3.80 (2.26, s, OCH3), 
4.05 (0.49H, d, J = 6.1 Hz, NCH2), 4.50 (0.25H, t, J = 5.9 Hz, NH), 4.55 (1.51H, d, J = 5.7 Hz, 
NCH2), 5.95 (0.75H, br s, NH), 6.78-6.82 (0.48H, m, H-3’), 6.86-6.91 (1.51H, m, H-3’), 7.02-7.07 
(0.75H, m, H-5), 7.08-7.13 (0.5H, m, H-2’), 7.25-7.29 (2.1H, m, H-4, H-2’), 7.31 (0.5H, d, J = 8.3 
Hz), 7.58 (0.74H, dd, J = 8.0, 1.1 Hz, H-6), 7.73-7.77 (0.5H ,m); 13C NMR (CDCl3, 125 MHz)  
20.2, 21.7, 43.7, 46.9, 55.4, 55.5, 114.4, 114.2, 125.8, 126.8, 127.2, 127.3, 128.4, 129.4, 129.9, 
130.0, 134.0, 135.7, 137.0, 138.8, 143.6, 159.5, 159.3, 169.2; HRMS [M+H]+ (C16H17BrNO2) calcd 
334.0437, obsd 334.0438. 
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3-Bromo-N,N-bis(4-methoxybenzyl)benzenesulfonamide (13). NaH (60% in mineral oil, 75 mg; 
1.86 mmol) was added to a solution of 3-bromobenzenesulfonamide (0.2 g, 0.85 mmol) in DMF 
(2mL) and the solution was stirred at stirred at room temperature for 5 min. 4-Methoxybenzyl 
chloride (0.25 mL, 1.86 mmol) was added dropwise, and the mixture was stirred at 80 °C for 2 h 
and saturated aqueous ammonium chloride solution (5 mL). The resulting solution was extracted 
with DCM (3 x 20 mL), and the combined organic phases were dried (MgSO4), and concentrated in 
vacuo.  Purification by chromatography on silica, using a gradient elution of 100% EtOAc to Petrol: 
EtOAc (5:1) gave the title compound as a crystalline white solid (0.34 g; 84%); mp 136-137 °C; IR 
3009, 2837, 1608, 1509 cm-1; 1H NMR (CDCl3, 500 MHz)  3.79 (6H, s, OCH3), 4.27 (4H, s, 
NCH2), 6.78 (4H, d, J = 8.6 Hz, H-3’), 7.01 (4H, d, J = 8.6 Hz, H-2’), 7.35 (1H, dd, J = 7.9, 8.0 Hz, 
H-5), 7.67 (1H, br d, J = 7.9 Hz, H-4), 7.72 (1H, br d, J = 7.9 Hz, H-6), 7.83 (1H, m, H-2); 13C 
NMR (CDCl3, 125 MHz)  49.8, 55.4, 114.0, 125.7, 127.3, 130.0, 130.1, 130.6, 135.4, 159.3; 
HRMS [M+H]+ (C22H23BrNO4S) calcd 476.0526, obsd 476.0522. 
3-Chloro-N,N-bis(4-methoxybenzyl)-2-methylbenzenesulfonamide (14). To a solution of 3-
chloro-2-methylbenzenesulfonamide (0.8 g, 3.89 mmol) in DMF (5 mL) was added NaH (60% in 
mineral oil, 0.2 g, 8.56 mmol) followed by 4-methoxybenzyl chloride (1.16 mL, 8.56 mmol). After 
stirring at room temperature for 1 h, saturated aqueous NH4Cl solution (5 mL) was added to the 
reaction mixture, followed by H2O (10 mL). The resulting solution was extracted with EtOAc (3 x 
20 mL), and the combined organic fractions were washed with brine, dried (MgSO4,) and the 
solvent was removed in vacuo. Purification by chromatography on silica using gradient elution of 
100% Petrol to 30% Petrol:EtOAc (3:1) afforded the benzenesulfonamide as a colourless crystalline 
solid (1.52 g, 88%); mp 66-68 °C; IR 2838, 1611, 1511 cm-1; 1H NMR (CDCl3, 500 MHz)  2.63 
(3H, s, Ar-CH3), 3.80 (6H, s, OCH3), 4.25 (4H, s, NCH2), 6.81 (4H, d, J = 8.6 Hz, H-3’), 6.96 (4H, 
d, J = 8.6 Hz, H-2’), 7.23 (1H, dd, J = 7.9, 8.0 Hz, H-5), 7.59 (1H, dd, J = 8.0, 1.0 Hz, H-4), 7.89 
(1H, dd, J = 7.9, 1.1 Hz, H-6); 13C NMR (500 MHz,CDCl3) 17.0, 48.8, 55.4, 114.1, 126.6, 127.2, 
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128.8, 130.2, 133.6, 135.9, 137.2, 140.9, 159.4; HRMS [M]+ (C23H24ClNO4S) calcd 445.1108, obsd 
445.1109. 
N-(4-Methoxybenzyl)-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
(15). A mixture of 12 (0.16 mg, 0.49 mmol), bis(pinacolato)diboron (0.19 g, 0.74 mmol), [1,1′-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (17 mg, 0.024 mmol), 1,1′-
Bis(diphenylphosphino)ferrocene (26 mg, 0.048 mmol) and KOAc (0.144 g, 1.47 mmol) in dioxane 
(2 mL) was purged with N2 and heated under microwave irradiation at 150 °C for 90 min. After 
cooling, the reaction mixture was filtered through Celite, EtOAc (10 mL) was added, and the 
mixture was washed with brine (2 x 10 mL), dried (MgSO4), and the solvents were evaporated 
under reduced pressure. Purification by chromatography on silica, employing a gradient eluent of 
Petrol:EtOAc (10:1) to Petrol:EtOAc (1:1), yielded the title compound as a colourless syrup (0.144 
g, 77%); IR 3484, 3181, 2980, 2933, 1644, 1612, 1580, 1512 cm-1; 1H NMR (CDCl3, 500 MHz)  
1.34 (12H, s, CH3), 2.44 (0.6H, s, Ar-CH3), 2.60 (2.4H, s, Ar-CH3), 3.78 (0.6H, s, OCH3), 3.80 
(2.4H, s, OCH3), 4.05 (0.4H, d, J = 6.1 Hz, NCH2), 4.51 (0.2H, t, J = 5.9 Hz, NH), 4.56 (1.6H, d, J 
= 5.6 Hz, NCH2), 5.88 (0.8H, t, J = 4.9 Hz, NH), 6.78-6.82 (0.4H, m, H-3’), 6.85-6.90 (1.6H, m, H-
3’), 7.08-7.12 (0.4H, m, H-2’), 7.17 (0.8H, dd, J = 7.5, 7.6 Hz, H-5), 7.26-7.29 (1.6H, m, H-2’), 
7.31 (0.4H, d, J = 8.3 Hz), 7.38 (0.8H, dd, J = 7.6, 1.4 Hz, H-4), 7.74-7.80 (1H, m, H-6); 13C NMR 
(CDCl3, 125 MHz)  19.1, 21.6, 24.9, 43.5, 46.9, 55.4, 55.4, 83.8, 114.2, 114.3, 124.9, 127.3, 128.3, 
129.1, 129.3, 129.4, 129.8, 130.3, 137.0, 137.3, 137.4, 141.8, 143.6, 159.2, 159.5, 170.6; HRMS 
[M]+ (C22H28BNO4) calcd 381.2220, obsd 381.2222. 
N,N-bis(4-Methoxybenzyl)-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzenesulfonamide (16). A mixture of 14 (0.18 mg, 0.41 mmol), bis(pinacolato)diboron (0.16 
g, 0.62 mmol), [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (14 mg, 0.02 mmol), 
1,1′-Bis(diphenylphosphino)ferrocene (22 mg, 0.04 mmol) and KOAc (0.119 g, 1.21 mmol) in 
dioxane (2 mL) was purged under N2 for 10 min, and heated under microwave conditions 150 °C 
for 120 min. The cooled reaction mixture was filtered through Celite, diluted with EtOAc (10 mL), 
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and washed with brine (3 x 10 mL). The combined organic fractions were dried (MgSO4,) and the 
solvent was remove under reduced pressure. Purification by chromatography on silica) using a 
gradient elution of Petrol:EtOAc (10:1) from Petrol:EtOAc (1:1) afforded the title compound as a 
white solid (87 mg, 40%); mp 126-128 °C ; IR 2981, 2158, 1610, 1510 cm-1; 1H NMR (CDCl3, 500 
MHz)  1.38 (12H, s, CH3), 2.79 (3H, s, Ar-CH3), 3.79 (6H, s, OCH3), 4.23 (4H, s, NCH2), 6.76-
6.81 (4H, m, H-3’), 6.92-6.98 (4H, m, H-2’), 7.28 (1H, dd, J = 7.8, 7.4 Hz, H-5), 7.95 (1H, dd, J = 
7.4, 1.3 Hz, H-4), 8.07 (1H, dd, J = 7.8, 1.4 Hz, H-6); 13C NMR (CDCl3, 125 MHz): 19.1, 25.0, 
48.6, 55.4, 84.1, 114.0, 125.2, 127.7, 130.2, 132.6, 139.0, 140.2, 144.6, 159.2; HRMS [M]+ 
(C29H36NO6BS) calcd 537.2465, obsd 537.2465. 
6-Acylamino-2-amino-4-cyclohexylmethoxy-5-nitrosopyrimidines: Method I. General 
Procedure. To a solution of 2,6-diamino-4-cyclohexylmethoxy-5-nitrosopyrimidine18 (17) (1.0 
mol. equiv.) in DMF (5-10 mL) was added the appropriate anhydride (1.1 mol. equiv.), and the 
mixture was heated at 80 C° for the specified time. After cooling, volatiles were removed under 
reduced pressure, water (10-20 mL) was added, and the reaction mixture was extracted with EtOAc 
(3 x 20 mL). The combined organic fractions were dried (Na2SO4), concentrated in vacuo, and the 
required acylaminopyrimidines (18-23) were isolated by chromatography on silica as described. 
6-Acetylamino-2-amino-4-cyclohexylmethoxy-5-nitrosopyrimidine (18). Prepared from 17 (0.50 
g, 2.0 mmol) and acetic anhydride (4 mL) in accordance with Method I, and purified by 
chromatography on silica (eluent DCM:MeOH, 10:1) to furnish 18 as an aquamarine crystalline 
solid (0.35 g; 60%); mp 149-150 C; 1H NMR (d6-DMSO, 300 MHz)  1.13-1.29 (5H, m, 
cyclohexyl), 1.79-1.94 (6H, m, cyclohexyl), 2.57 (3H, s, Me), 4.45 (2H, d, J = 6.3, CH2O), 8.73 (2 
H, br s, NH2), 12.3 (1 H, br s, NH). HRMS [M]
+ (C13H19N5O3) calcd 293.1488, obsd 293.1484. 
Anal. (C13H19N5O3 + 0.05 EtOAc) C, H, N. 
2-Amino-4-cyclohexylmethoxy-5-nitroso-6-propionylaminopyrimidine (19). Synthesized from 
17 (0.50 g, 2.0 mmol) and propionic anhydride (0.29 g, 2.2 mmol) in DMF (6.0 mL) following 
Method I; purified by chromatography on silica employing Petrol: EtOAc (3:2) as eluent, to give 
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the title compound as an aquamarine crystalline solid (0.28 g, 46%): mp 160-161 C; 1H NMR (d6-
DMSO, 300 MHz)  1.11-1.18 (3H, t, J = 7.3 Hz, CH2CH3), 1.23-1.30 (5H, m, cyclohexyl), 1.78-
1.94 (6H, m, cyclohexyl), 2.95 (2H, q, J = 7.3 Hz , CH2CH3), 4.44 (2H, d, J = 6.3 Hz , CH2O), 8.72 
(2H, br s, NH2), 12.4 (1 H, br s, NH); HRMS [M]
+ (C14H21N5O3) calcd 307.1644, obsd 307.1632. 
Anal. (C14H21N5O3 + 0.3 EtOAc) C, H, N. 
2-Amino-4-cyclohexylmethoxy-6-isobutylamino-5-nitrosopyrimidine (20). From 17 (0.82 g, 
3.25 mmol) and isobutyric anhydride (0.57 g 3.57 mmol) in DMF (12 mL) employing Method I; 
purification by chromatography on silica with Petrol:EtOAc (3:2) as eluent, followed by 
recrystallisation from EtOAc-Petrol to furnish 20 as a pale blue crystalline solid (0.63 g, 60%); mp 
180-181 oC; 1H NMR (d6-DMSO, 300 MHz)  0.92-1.39 (5H, m, cyclohexyl), 1.22 (6H, d, J = 6.8 
Hz , CH(CH3)2), 1.78-1.93 (6 H, m, cyclohexyl), 3.26 (1H, quin, J = 6.8 Hz, CH(CH3)2), 4.44 (2 H, 
d, J = 6.8 Hz, CH2CH), 8.74 (2 H, br s, NH2), 12.6 (1 H, br s, NH). Anal. (C15H23N5O3) C, H, N. 
2-Amino-6-benzoylamino-4-cyclohexylmethoxy-5-nitrosopyrimidine (21). Synthesized 
following Method I from 17 (0.50 g, 2.0 mmol) and benzoic anhydride (0.50 g; 2.2 mmol) in DMF 
(8 mL), and isolated by chromatography on silica using DCM:MeOH (95:5) as eluent. 
Recrystallisation from EtOAc-Petrol yielded 21 as a blue crystalline solid (0.24 g; 33.8%); mp 210-
211 oC; 1H NMR (d6-DMSO, 300 MHz)  1.16-1.43 (5H, m, cyclohexyl), 1.81-1.98 (6 H, m, 
cyclohexyl), 4.50 (2H, d, J = 6.3 Hz, OCH2), 7.75-7.86 (3H, m, Ar-H), 8.08-8.12 (2H, m, Ar-H), 
8.88 (1 H, br s, NH), 8.99 (1H, br s, NH), 13.8 (1H, br s, NH); HRMS [M]+ (C18H21N5O3) calcd 
355.1644, obsd 355.1646. Anal. (C18H21N5O3) C, H, N. 
2-Amino-6-(2-chlorobenzoyl)amino-4-cyclohexylmethoxy-5-nitrosopyrimidine (22). To a 
stirred solution of 17 (0.50 g, 2.00 mmol) and N,N-dimethyl-4-aminopyridine (24 mg, 0.20 mmol) 
in pyridine (12 mL), was added 2-chlorobenzoyl chloride (280 L, 2.20 mmol). The solution was 
stirred at 25 °C under N2 for 18h, concentrated under reduced pressure, and the residual solid was 
dissolved in DCM (40 mL) and washed with aqueous hydrochloric acid solution (5% v/v, 3 x 20 
mL). The organic fraction was dried (Na2SO4) and the solvent was removed in vacuo to give a dark 
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green solid, which was recrystallized from EtOAc-Petrol to furnish the title compound as a blue-
green crystalline solid (0.6 g; 78%); mp 184-185 °C; IR 3467, 3202, 2925, 1728, 1594, 1536 cm-1; 
1H NMR (d6-DMSO, 300 MHz)  0.94-1.28 (5H, m, cyclohexyl), 1.60-1.97 (6H, m, cyclohexyl), 
4.35 (2H, d, J = 6.6 Hz, OCH2), 6.15 (2H, s, NH2), 7.32-7.53 (3H, m, Ar-H), 7.54 (1H, d, Ar-H); 
13C NMR, (d6-DMSO, 75 MHz)  26.0, 26.7, 30.0, 37.5, 74.0, 127.7, 129.9, 131.3, 132.0, 132.8, 
135.1, 139.6, 164.9, 166.6; MS (ES+) m/z 390 [M(35Cl)+H]+, 392 [M(37Cl)+H]+. Anal. 
(C18H20ClN5O3 + 0.1 EtOAc) C, H, N. 
2-Amino-4-cyclohexylmethoxy-6-(2-methylbenzoyl)amino-5-nitrosopyrimidine (23). Prepared 
analogously to 22 above from 17 (0.51 g, 2.00 mmol) and 2-methylbenzoyl chloride (300 L, 2.20 
mmol) in pyridine (12 mL). Recrystallisation from EtOAc-Petrol gave a dark blue crystalline solid 
(0.57 g; 77%); mp 177-179 °C; IR 3418, 3233, 2916, 1713, 1598, 1520 cm-1; 1H NMR (d6-DMSO, 
300 MHz)  0.94-1.28 (5H, m, cyclohexyl), 1.60-1.95 (6H, m, cyclohexyl), 2.47 (3H, s, ArCH3), 
4.35 (2H, d, J = 6.7 Hz, OCH2), 6.17 (1H, s), 7.22-7.57 (3 H, m, Ar-H), 7.57 (1H, s), 7.59 (1H, d, J 
= 1.2 Hz); 13C NMR, (d6-DMSO, 75 MHz)  21.0, 26.0, 26.7, 30.1, 37.5, 73.9, 126.8, 128.3, 132.2, 
132.3, 134.5, 138.8, 139.8, 165.1, 168.9; MS (ES+) m/z 370 [M+H]+. Anal. (C19H23N5O3) C, H, N. 
8-Substituted 2-amino-6-cyclohexylmethoxypurines: Method II. General Procedure. A stirred 
solution of the appropriate 6-acylamino-2-amino-4-cyclohexylmethyloxy-5-nitrosopyrimidine (0.5-
2.0 mmol) in THF (20-30 mL) containing AcOH (glacial, 1-2 mL) was cooled to -78 °C and purged 
with N2, prior to addition of Pd (10% on carbon, 15% w/w). The reaction mixture was stirred under 
H2 at atmospheric pressure for 24 h at ambient temperature, filtered through Celite, and the filtrate 
was neutralised with saturated NaHCO3 solution (30-50 mL) and extracted with EtOAc (3 x 30 
mL). The combined organic fractions were dried (Na2SO4) and evaporated under reduced pressure 
to give the required 8-substituted purine. Compound purification was achieved by chromatography 
on silica and recrystallisation as described. 
2-Amino-6-cyclohexylmethoxy-8-methylpurine (24). Prepared in accordance with Method II 
from 18 (0.35 g, 1.20 mmol), and isolated by chromatography on silica employing DCM:MeOH 
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(10:1) as eluent. Recrystallisation from a mixture of EtOAc-MeOH gave 24 as a cream crystalline 
solid (0.19 g, 60%); mp 99-100 °C; 1H NMR (d6-DMSO, 300 MHz)  1.08-1.45 (5 H, m, 
cyclohexyl), 1.78-1.92 (6 H, m, cyclohexyl), 2.42 (3H, s, Me), 4.26 (2 H, d, J = 6.2 Hz, OCH2), 
6.20 (2 H, br s, NH2), 12.2 (1 H, br s, NH); HRMS [M]
+ (C13H19N5O) calcd 261.1590, obsd 
261.1587. Anal. (C13H19N5O + 1.15 MeOH) C, H, N. 
2-Amino-6-cyclohexylmethoxy-8-ethylpurine (25). Synthesised by Method II from pyrimidine 19 
(0.28 g, 0.91 mmol) and isolated by chromatography on silica employing Petrol:EtOAc (3:2) as 
eluent. Recrystallisation from a mixture of EtOAc-Et2O gave 25 as a cream solid. (0.10 g, 39.9%); 
mp 137-138 °C; 1H NMR (d6-DMSO, 300 MHz)  1.06-1.18 (5 H, m, cyclohexyl), 1.31 (3 H, t, J = 
7.5 Hz, CH2CH3), 1.76-1.90 (6 H, m, cyclohexyl), 2.74 (2 H, q, J = 7.5 Hz, CH2CH3), 4.23 (2 H, d, 
J = 6.1 Hz, OCH2), 6.18 (2 H, br s, NH2), 12.2 (1 H, br s, NH); HRMS [M]
+ (C14H21N5O) calcd 
275.1746, obsd 275.1743. Anal. (C14H21N5O + 0.1 EtOAc) C, H, N. 
2-Amino-6-cyclohexylmethoxy-8-isopropylpurine (26). In accordance with Method II from 20 
(0.63 g; 2.0 mmol). Isolated by chromatography on silica with DCM:MeOH (10:1) as eluent, 
followed by recrystallisation from EtOAc-Et2O to yield the title purine as a cream crystalline solid 
(0.39 g; 70%); mp 136-138 °C; 1H NMR (d6-DMSO, 300 MHz)  1.08-1.19 (5 H, m, cyclohexyl), 
1.36 (6 H, d, J = 6.9 Hz, CH(CH3)2) 1.79-1.92 (6 H, m, cyclohexyl), 3.07 (1 H, quin, J = 6.9 Hz, 
(CH(CH3)2), 4.25 (2 H, d, J = 6.1 Hz, OCH2), 6.20 (2 H, br s, NH2), 12.6 (1 H, s, NH). (C15H23N5O 
+ 0.25 H2O) C, H, N. 
2-Amino-6-cyclohexylmethoxy-8-phenylpurine (27). Prepared following Method II from 21 (0.24 
g, 0.67 mmol) and isolated by chromatography on silica employing DCM:MeOH (10:1) as eluent. 
Recrystallisation from MeOH-EtOAc gave 27 as pale pink crystals (0.16 g, 76%); mp 271-272 °C; 
1H NMR (d6-DMSO, 300 MHz)  1.12-1.31 (5H, m, cyclohexyl), 1.81-1.97 (6H, m, cyclohexyl), 
4.33 (2H, d, J = 6.2 Hz, OCH2), 6.43 (2H, br s, NH2), 7.56-7.60 (3H, m, Ar-H), 8.16 (2 H, m, Ar-
H), 13.0 (1H, br s, NH); HRMS [M]+ (C18H21N5O) calcd 323.1746, obsd 323.1746. (C18H21N5O + 
0.4 MeOH) C, H, N. 
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2-Amino-8-(2-chlorophenyl)-6-cyclohexylmethoxypurine (28). Prepared from 22 (375 mg; 0.971 
mmol) following Method II, and purified by chromatography on silica employing EtOAc: Petrol 
(2:1), to afford the title compound as an off-white powder (241 mg, 70%); mp 190-191 °C; IR 
3487, 3289, 3171, 2021, 1578 cm-1; 1H NMR (d6-DMSO, 300 MHz)  1.02-1.33 (5H, m, 
cyclohexyl), 1.64-1.83 (6H, m, cyclohexyl), 4.23 (2H, d, J = 6.24 Hz, OCH2), 6.34 (2H, br s, NH2), 
7.45-7.54 (2H, m, Ar-H), 7.61-7.64 (1H, m, Ar-H), 7.73-7.75 (1H, m, Ar-H), 12.69 (1 H, br s, NH); 
13C NMR, (d6-DMSO, 75 MHz)  25.6, 26.4, 29.6, 37.2, 70.9, 114.7, 127.6, 130.4, 130.5, 131.3, 
132.2, 145.1, 156.2, 160.2, 160.8; MS (ES+) m/z 358 [M(35Cl)+H]+, 360 [M(37Cl)+H]+. Anal. 
(C18H20ClN5O + 0.1 EtOAc) C, H, N. 
2-Amino-6-cyclohexylmethoxy-8-(2-methylphenyl)purine (29). Synthesized in accordance with 
Method II from 23 (327 mg; 0.88 mmol) and purified by chromatography on silica with 
EtOAc:Petrol (2:1); pale yellow powder (302 mg, 100%); mp 187-188 °C; IR 3480, 3310, 3179, 
3085, 2045, 1582 cm-1; 1H NMR (d6-DMSO, 300 MHz)  1.01-1.29 (5H, m, cyclohexyl), 1.64-1.84 
(6H, m, cyclohexyl), 2.54 (3H, s, Ar-CH3), 4.25 (2H, d, J = 6.4 Hz, OCH2), 6.28 (2H, br s, NH2), 
7.28-7.38 (3H, m, Ar-H), 7.64 (1H, m, Ar-H), 12.60 (1H, br s, NH); 13C NMR, (d6-DMSO, 75 
MHz)  21.3, 25.5, 26.3, 29.6, 37.2, 70.9, 114.9, 126.2, 129.3, 129.6, 130.3, 131.4, 137.6, 147.8, 
156.3, 160.0, 160.6; MS (ES+) m/z 338 [M+H]+; HRMS [M+H]+ (C19H24N5O) calcd 338.1975 
found 338.1973; [M-H]- (C19H22N5O) calcd 336.1830 found 336.1826. Anal. (C19H23N5O + 0.2 
EtOAc) C, H, N. 
Purine 29 was also synthesised by the following alternative method: a mixture of 8-bromo-6-
(cyclohexylmethoxy)-9H-purin-2-amine (83 mg; 0.25 mmol), o-tolyl boronic acid (69 mg; 0.51 
mmol), Cs2CO3 (166 mg; 0.51 mmol) and dichloro [1,1' bis(di-tert-butylphosphino)]ferrocene 
palladium (II) (8 mg; 0.01 mmol) in toluene (15 mL) was degassed with nitrogen and heated under 
at 100 °C with stirring for 3 h. After cooling, the reaction mixture was filtered through Celite, and 
the filtrate was concentrated under reduced pressure to give a yellow solid. The crude material was 
purified by chromatography on silica, employing a gradient of Petrol:EtOAc (1:1 to 0:1) as eluent to 
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afford 29 as a beige-white solid (60 mg; 70%). All analytical data (mp, NMR, MS) were identical 
with 29 prepared previously. 
2,4,6-Triamino-5-cyclohexylmethoxypyrimidine (30). Zinc powder (0.26 g, 3.9 mmol) was added 
to a solution of 2,6-diamino-4-cyclohexylmethoxy-5-nitrosopyrimidine (17, 0.20 g, 0.79 mmol) in 
AcOH (5 mL), and the solution was stirred for 12 h at room temperature. The reaction mixture was 
filtered through Celite and the filtrate was evaporated under reduced pressure to furnish a yellow 
solid, which was redissolved in water (20 mL) and the solution was adjusted to pH 7.0 with 
saturated aqueous sodium bicarbonate solution. The mixture was extracted with EtOAc (3 x 30 
mL), the combined organic layers were dried (Na2SO4), and the solvent was removed in vacuo to 
give a pale yellow solid. Recrystallisation from MeOH afforded the title compound (0.14 g, 74%); 
mp 151-153 °C; IR 3446, 3390, 3309, 3178, 2918, 2847, 1613, 1577 cm-1; 1H NMR (d6-DMSO, 
300 MHz)  0.92-1.29 (5H, m, cyclohexyl), 1.67-1.79 (6H, m, cyclohexyl), 3.39 (2H, br, NH2), 3.93 
(2H, d, J = 6.0 Hz, OCH2), 5.27 (2H, br, NH2), 5.66 (2H, br, NH2); 
13C NMR, (d6-DMSO, 75 MHz) 
 24.9, 25.7, 28.9, 36.7, 69.6, 99.9, 155.2, 155.4, 157.8; HRMS [M]+ (C11H19N5O) calcd 237.1587, 
obsd 237.1590. Anal. (C11H19N5O + 0.1 H2O) C, H, N. 
2,5-Diamino-4-cyclohexylmethoxy-6-(2,2,2-trifluoroacetyl)aminopyrimidine (31). A solution of 
30 (171 mg; 0.72 mmol) in TFA (5 mL) was heated under reflux for 6 h, and the solvent was 
evaporated in vacuo. The title compound was isolated as a yellow solid (213 mg; 91%) by 
chromatography on silica using DCM:MeOH, (9:1) as eluent, and used directly for the next 
reaction; 1H NMR (d6-DMSO, 300 MHz)  0.95-1.17 (5H, m, cyclohexyl), 1.64-1.67 (6H, m, 
cyclohexyl), 3.98 (2H, d, J = 3.9, OCH2), 6.98 (2H, br s, NH2), ), 7.24 (2H, br s, NH2), 9.97 (1H, s, 
NHCO); MS (ES+) m/z 334 [M+H]+. 
2-Amino-6-cyclohexylmethoxy-8-trifluoromethylpurine (32). To a solution of 31 (213 mg; 0.64 
mmol) in pyridine (6 mL) was added N,N-dimethyl-4-aminopyridine (21 mg; 0.17 mmol) and the 
mixture was heated under reflux for 5 days. The residual red oil remaining, following removal of 
the solvent under reduced pressure, was purified by chromatography on silica utilising using DCM: 
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MeOH (95:5) furnished the title compound as a pale orange crystalline solid (106 mg; 53%); mp 
252-253 °C; IR 3496, 1632, 1585 cm-1; 1H NMR (d6-DMSO, 300 MHz)  0.97-1.32 (5 H, m, 
cyclohexyl), 1.63-1.81 (6 H, m, cyclohexyl), 4.23 (2H, d, J = 6.2 Hz, OCH2), 6.76 (2H, br s, NH2), 
13.71 (1H, s, NH); 13C NMR (d6-DMSO, 75 MHz)  25.5, 26.3, 29.5, 37.1, 71.3, 114.2, 117.7, 
121.3, 124.8, 155.3, 160.5, 161.9; MS (ES+) m/z 316 [M+H]+. Anal. (C13H16F3N5O + 0.1 H2O) C, 
H, N. 
2-Amino-9-benzyl-6-cyclohexylmethoxypurine (33). To a solution of 5 (2.60 g, 10.5 mmol) in 
DMF (20 mL) was added K2CO3 (7.3 g, 52.6 mmol) and benzyl bromide (1.5 mL, 12.6 mmol), and 
the mixture was stirred at room temperature for 12 h. Volatiles were removed in vacuo, and the 
residual oil was redissolved in EtOAc (20 mL), washed with water (3 x 25 mL), and the organic 
fraction was dried (Na2SO4) and evaporated under reduced pressure. Purification by 
chromatography on silica, using EtOAc/Petrol (1:1) as eluent, gave the 9-benzylpurine (33) as a 
white solid (1.04 g, 29%); IR 3394, 3341, 3225, 3123, 2923, 2851, 1733, 1643, 1518 cm-1; 1H NMR 
(d6-DMSO, 300 MHz) 0.95-1.27 (5H, m, cyclohexyl), 1.61-1.95 (6H, m, cyclohexyl), 4.21 (2H, d, 
J = 6.3 Hz, OCH2), 5.25 (2H, s, CH2Ph), 6.42 (2H, s, NH2), 7.15-7.40 (5H, m, Ar-H), 7.95 (1H, s, 
purine C8-H); 13C NMR (d6-DMSO, 75 MHz) 26.1, 26.8, 30.2, 37.8, 47.2, 72.4, 116.0, 128.0, 
128.5, 129.3, 136.4, 139.3, 154.7, 159.9, 162.3. 
9-Benzyl-8-(3-(benzyloxy)-2-methylphenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine (34) 1-
Benzyloxy-3-bromo-2-methylbenzene (616 mg, 2.22 mmol) and caesium carbonate (604 mg, 1.85 
mmol) were added to a solution of 33 (250 mg, 0.74 mmol) in DMF (15 mL). The mixture was 
purged with N2 for 15 min, prior to addition of copper (I) iodide (423 mg, 2.22 mmol) and 
Pd(OAc)2 (0.1M in DMF, 0.37 mL), and heated for 40 minutes under microwave irradiation at 200 
°C. The solvent was removed under reduced pressure, and the residual oil was redissolved in EtOAc 
(25 mL) and washed with water (3 x 25 mL), dried (Na2SO4), and the organic fraction was 
evaporated in vacuo. The product was purified by chromatography on silica with Petrol:AcOEt 
(2:1) as eluent, to furnish the title compound as a pale yellow solid (190 mg, 48%); IR: 3376, 3346, 
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3223, 2923, 2848, 1648, 1605, 1578 cm-1; 1H NMR (CDCl3, 300 MHz)  0.95-1.15 (5H, m, 
cyclohexyl), 1.50-1.95 (6H, m, cyclohexyl), 1.85 (3H, s, Ar-CH3), 4.23 (2H, d, J = 6.0 Hz, OCH2), 
4.84 (2H, br s, NH2), 4.99 (2H, s, N-CH2-Ar), 5.04 (2H, s, O-CH2-Ar), 6.71-7.40 (13H, m, Ar-H); 
13C NMR (CDCl3, 75 MHz)  13.5, 26.2, 26.9, 30.3, 37.9, 46.7, 70.9, 72.5, 113.8, 123.3, 126.6, 
127.5, 127.9, 128.0, 128.2, 128.7, 128.9, 129.3, 131.9, 136.9, 137.7, 157.5, 159.7. 
Benzyl 3-(2-amino-9-benzyl-6-(cyclohexylmethoxy)-9H-purin-8-yl)-2-methyl benzoate (35). 
Synthesised in a manner analogous to that for 34 above, from 33 (250 mg, 0.74 mmol) and benzyl 
3-bromo-2-methylbenzoate (678 mg, 2.22 mmol); Purification by chromatography on silica with 
Petrol:AcOEt (2:1) as eluent, gave the title compound as a yellow powder (131 mg, 32%); IR 3349, 
3225, 2923, 2851, 1721, 1653, 1603, 1580 cm-1; 1H NMR (CDCl3, 300 MHz)  0.92-1.17 (5H, m, 
cyclohexyl), 1.55-1.97 (6H, m, cyclohexyl), 2.18 (3H, s, ArCH3), 4.32 (2H, d, J = 6.0 Hz, OCH2), 
4.93 (2H, s, NH2), 5.05 (2H, s, N-CH2-Ar), 5.37 (2H, s, O-CH2-Ar), 6.82-6.87 (2H, m, Ar-H), 7.10-
7.50 (10H, m, Ar-H), 8.01 (1H, d, J = 7.5 Hz, Ar-H); 13C NMR (CDCl3, 75 MHz)  18.2, 26.1, 
26.9, 30.3, 37.8, 46.7, 67.2, 72.5, 115.7, 125.6, 128.0, 128.5, 128.6, 128.8, 128.9, 131.8, 132.2, 
132.6, 134.3, 136.4, 136.6, 140.6, 149.2, 155.6, 159.8, 162.1, 167.5. 
3-(2-Amino-6-cyclohexylmethoxy-9H-purin-8-yl)-2-methylphenol (36). To a solution of 34 (125 
mg, 0.23 mmol) in acetic acid (10 mL), containing hydrochloric acid (12M, 0.25 mL), was added 
Pd (10% on carbon, 125 mg), and the reaction mixture was stirred under H2 at atmospheric pressure 
for 12 h. Water (10 mL) was added, and the mixture was heated under reflux for 1h, filtered through 
Celite, and the solvents were evaporated under reduced pressure. Purification by semi-preparative 
HPLC afforded the title compound as white crystals (11 mg, 13%); 1H NMR (d6-DMSO, 300 MHz) 
 0.99-1.84 (m, 11H, cyclohexyl), 2.17 (3H, s, Ar-CH3), 4.21 (2H, d, J = 6.3 Hz, OCH2), 6.80 (1H, 
d, J = 7.8 Hz, Ar-H), 6.90 (1H, d, J = 7.5 Hz, Ar-H), 6.99-7.05 (1H, dd, J = 7.8, 7.5 Hz, Ar-H), 8.43 
(2H, br s, NH2); HRMS [M+H]
+ (C19H24N5O2) calcd 354.1925, obsd 354.1925. 
3-(2-Amino-6-cyclohexylmethoxy-9H-purin-8-yl)-2-methylbenzoic acid (37). Prepared as 
described for 36 from 35 (105 mg, 0.19 mmol) and Pd (10% on carbon, 105 mg); purification by 
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semi-preparative HPLC gave the title compound as a white powder (17 mg, 24%); 1H NMR d6-
DMSO, 300 MHz)  0.99-1.71 (m, 11H, cyclohexyl), 2.36 (3H, s, ArCH3), 4.21 (2H, d, J = 6.3 Hz, 
CH2), 7.15-7.20 (1H, m, Ar-H), 7.34 (1H, dd, J = 1.2, 7.5 Hz, Ar-H), 7.41 (1H, dd, J = 1.2, 7.5 Hz, 
Ar-H); 13C NMR (d6-DMSO, 75 MHz) 18.3, 27.3, 27.9, 31.0, 31.3, 39.3, 41.1, 73.3, 126.7, 129.9, 
130.7, 132.6, 135.2, 142.8, 145, 150.0, 161.8; HRMS [M+H]+ (C20H24N5O3) calcd 382.1874, obsd 
382.1872. 
2-Amino-6-cyclohexylmethoxy-purine-9-carboxylic acid t-butyl ester (38). To a stirred 
suspension of 5 (98.4 mg; 4.0 mmol) and potassium carbonate (67.1 mg; 4.8 mmol) in DMF (12 
mL) was added di-t-butyl dicarbonate (1.2 mL; 5.0 mmol), and the mixture was stirred at room 
temperature for 18 h. Water (20 mL) was added and the reaction mixture was stirred a further 1 h, 
whereupon the resulting white precipitate was collected and triturated with Et2O to give the product 
as a white solid (1.16 g; 84%); Rf = 0.61 (F); 
1H NMR (CDCl3, 300 MHz)  1.01-1.32 (5 H, m, 
cyclohexyl), 1.68 (9H, s, C(CH3)3), 1.74-1.92 (6H, m, cyclohexyl), 4.28 (2H, d, J = 6.3 Hz, OCH2), 
5.14 (2H, br s, NH2), 8.00 (1H, s, NH); 
13C NMR (CDCl3, 75 MHz)  26.1, 26.8, 28.4, 30.1, 37.6, 
72.5, 86.5, 137.7, 146.6, 153.9, 161.1, 162.3. HRMS [M]+ (C17H25N5O3) calcd 347.1948, obsd 
347.1957. 
2-Amino-8-bromo-6-cyclohexylmethoxypurine (39). To a stirred suspension of 38 (1.13 g; 3.26 
mmol) in MeCN (36 mL) and water (8.6 mL) was added N-bromosuccinimide (87.4 mg; 4.89 
mmol). The mixture was stirred at room temperature for 1 h, filtered, and the filtrate concentrated 
under reduced pressure to give a tan solid. Purification by chromatography on silica using gradient 
elution with EtOAc: Petrol (2:1) as eluent afforded the title compound as an off-white solid (442 
mg, 41.6%); mp 228-229 °C; IR 3482, 3303, 3163, 2921, 2850, 1623, 1563 cm-1; 1H NMR (CDCl3, 
300 MHz)  1.04-1.31 (5H, m, cyclohexyl), 1.70-1.91 (6H, m, cyclohexyl), 4.28 (2H, d, J = 5.8 Hz, 
OCH2), 5.10 (2 H, br s, NH2); 
13C NMR (CDCl3, 75 MHz): 26.1, 26.8, 30.1, 37.6, 72.8, 155.6, 
158.8, 161.0; HRMS [M]+ (C12H16BrN5O) calcd 325.0536, obsd 325.0538. 
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Bromopurine 39 was also prepared directly from 5 as follows: A mixture of 5 (1.0 g; 4.0 mmol) and 
pyridinium tribromide (2.58 g; 8.1 mmol) in DCM (10 mL) was stirred at 70 oC for 96 h. Saturated 
aqueous sodium metabisulfite solution (10 mL) was added, followed by water (10 mL), and the 
mixture was extracted with EtOAc (3 x 20 mL). The organic phase was washed with brine (2 x 10 
mL), dried (MgSO4) and concentrated in vacuo. The residual solid was purified by chromatography 
on silica, employing EtOAc: MeOH (10:1) as eluent, to give 39 as an off-white solid (0.39 g; 29%), 
identical (mp, NMR, MS) to that prepared above. 
PMB-protected 2-amino-8-aryl-6-cyclohexylmethoxypurines (40-42): Method III. General 
Procedure. A mixture of 39 (1.0 mol. equiv.), the appropriate benzamide (15) or sulfonamide (16) 
(1.0 mol. equiv.) dichloro [1,1' bis(di-tert-butylphosphino)]ferrocene palladium (II) (‘Pd-118’) (0.5 
mol. equiv.) and Cs2CO3 (2.0 mol. equiv.) in dioxane:H2O (4:1, 2.5 mL), was purged under N2 for 
15 min and stirred for 4 h at 110 °C. The reaction mixture was filtered through Celite, EtOAc (10 
mL) was added, and the organic fraction was washed sequentially with saturated aqueous NH4Cl 
and brine, dried over MgSO4, filtered and concentrated in vacuo. The target compound was isolated 
by chromatography on silica as described. 
3-(2-Amino-6-(cyclohexylmethoxy)-9H-purin-8-yl)-N-(4-methoxybenzyl)-2-methylbenzamide 
(40). Prepared in accordance with Method III from 39 (98 mg, 0.26 mmol) and 15 (84 mg, 0.26 
mmol). Purification by chromatography on silica using a gradient eluent of 100% DCM to 
DCM:MeOH (5:1) afforded the title compound as a beige solid (54 mg; 42%); mp 252-255 °C; IR 
3485, 3185, 2926, 1580, 1512 cm-1; 1H NMR (d6-DMSO, 500 MHz)  0.98-1.09 (2H, m, 
cyclohexyl), 1.13-1.32 (3H, m, cyclohexyl), 1.62-1.75 (3H, m, cyclohexyl), 1.77-1.87 (3H, m, 
cyclohexyl), 2.43 (3H, s, Ar-CH3), 3.74 (3H, s, OCH3), 4.24 (2H, d, J = 6.4 Hz, OCH2), 4.39 (2H, d, 
J = 6.0 Hz, NCH2), 6.28 (2H, s, NH2), 6.91 (2H, d, J = 8.7 Hz, H-3’), 7.28 (2H, d, J = 8.7 Hz, H-2’), 
7.32-7.41 (2H, m, H-4, H-5), 7.61 (1H, br d, J = 7.0 Hz, H-6), 8.87 (1H, t, J = 6.0 Hz, NH), 12.63 
(1H, s, N9-H); 13C NMR (d6-DMSO, 125 MHz)  17.3, 25.2, 26.0, 29.3, 36.8, 41.8, 55.0, 70.6, 
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113.7, 125.5, 127.6, 128.5, 130.4, 131.5, 139.2, 158.2, 159.7, 168.9; HRMS [M+H]+ (C28H33N6O3) 
calcd 501.2609, obsd 501.2598. 
3-(2-Amino-6-(cyclohexylmethoxy)-9H-purin-8-yl)-N,N-bis(4-methoxybenzyl) 
benzenesulfonamide (41). Prepared following Method III from 8-bromo-6-(cyclohexylmethoxy)-
9H-purin-2- amine 39 (32 mg, 0.098 mmol), except that the diisopropyl (3-(N,N-bis(4-
methoxybenzyl)sulfamoyl)phenyl)boronate was generated in situ as follows: to a solution of 3-
bromo-N,N-bis(4-methoxybenzyl)benzenesulfonamide 13 (62 mg, 0.13 mmol) in THF (2 mL), at -
78 °C was added n-BuLi (2.5 M in hexane, 55 L, 0.14 mmol) dropwise. The mixture was stirred 
for 10 min, triisopropylborate (35 L, 0.15 mmol) was added, and stirring was continued for a 
further 15 min at -78 oC. The reaction mixture was allowed to warm to room temperature overnight, 
and the solvent was evaporated under reduced pressure to give diisopropyl (3-(N,N-bis(4-
methoxybenzyl)sulfamoyl)phenyl)boronate (72 mg, 0.137 mmol) which was used directly. 
Purification by chromatography on silica, using a gradient elution from EtOAc:Petrol (65:15) to 
100% EtOAc, yielded the title compound as a white solid (18 mg; 29%); 1H NMR (CDCl3, 500 
MHz,)  0.91-1.05 (2H, m, cyclohexyl), 1.14-1.29 (3H, m, cyclohexyl), 1.63-1.87 (6H, m, 
cyclohexyl), 3.69 (6H, s, OCH3), 4.03-4.23 (6H, m, NCH2, OCH2), 4.94 (2H, s, NH2), 6.66 (4H, d,  
J = 8.1 Hz, H-3’), 6.85 (4H, d, J = 7.9 Hz, H-2’), 7.48 (1H, dd, J = 7.6, 7.9 Hz, H-3), 7.72 (1H, d,   
J = 7.6 Hz, H-4), 8.29 (1H, br s, H-6), 8.40 (1H, s, H-2); 13C NMR (CDCl3, 125 MHz)  25.8, 26.6, 
29.9, 37.2, 49.8, 55.3, 72.3, 113. 9, 116.6, 124.6, 127.5, 127.8, 129.8, 129.9, 130.4, 131.1, 141.9, 
146.6, 155.5, 159.2, 159.4, 161.7; HRMS [M+H]+ (C34H39N6O5S) calcd 643.2697, obsd 643.2693. 
3-(2-Amino-6-(cyclohexylmethoxy)-9H-purin-8-yl)-N,N-bis(4-methoxybenzyl)-2-
methylbenzenesulfonamide (42). Prepared in accordance with Method III from 39 (104 mg, 0.32 
mmol) and 16 (171 mg, 0.32 mmol). Purification by chromatography on silica) with a gradient 
elution of 100% DCM to DCM:MeOH (10:1) gave the title compound as an-off white solid (24 mg; 
24%); mp 209-210 °C; IR 3366, 2926, 1582, 1512 cm-1; 1H NMR (d6-DMSO, 500 MHz)  0.99-
1.11 (2H, m, cyclohexyl), 1.13-1.32 (3H, m, cyclohexyl), 1.63-1.76 (3H, m, cyclohexyl),1.78-1.88 
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(3H, m, cyclohexyl), 2.63 (3H, s, Ar-CH3), 3.72 (6H, s, OCH3), 4.21-4.30 (6H, m, OCH2, NCH2), 
6.35 (2H, s, NH2), 6.84 (4H, d, J = 8.7 Hz, H-3’), 6.98 (4H, d, J = 8.7 Hz, H-2’), 7.50 (1H, dd, J = 
7.3, 7.9 Hz, H-5), 7.84 (1H, d, J = 7.3 Hz, H-4), 7.95 (1H, d, J = 7.9 Hz, H-6), 12.76 (1H, s, N9-H); 
13C NMR (d6-DMSO, 125 MHz)  16.9, 25.2, 25.9, 29.3, 36.8, 48.9, 55.0, 70.6, 113.8, 114.5, 126.0, 
127.3, 129.7, 129.9, 133.7, 134.6, 136.3, 139.6, 146.0, 155.9, 158.7, 159.8, 160.4. HRMS [M+H]+ 
(C35H41N6O5S) calcd 657.2854, obsd 657.2840. 
2-Amino-8-aryl-6-cyclohexylmethoxypurines (43-45): Method IV. General Procedure. A 
solution of the appropriate PMB-protected 2-amino-8-aryl-6-cyclohexymethyloxypurine (0.04-0.2 
mmol) in TFA (1-2 mL) was stirred at the specified temperature until the reaction was complete. 
The reaction mixture was neutralised with saturated aqueous Na2CO3 solution, extracted with 
EtOAc (3 x 10 mL), and the combined organic fractions were dried (MgSO4) filtered and 
evaporated in vacuo. The target compounds were isolated by chromatography on silica as described. 
3-(2-Amino-6-(cyclohexylmethoxy)-9H-purin-8-yl)-2-methylbenzamide (43). Synthesised from 
40 (90 mg, 0.18 mmol) and TFA (1 mL) (48 h, 110 C) following Method IV. Purification by 
chromatography on silica, using a gradient elution of 100% EtOAc to EtOAc:MeOH (5:1), gave the 
required purine as a white solid (4 mg; 6 %); mp 271-272 °C; IR 3379, 3210, 2932, 2857, 1662, 
1624, 1591, 1574, 1533 cm-1; 1H NMR (d6-DMSO, 500 MHz,)  1.02-0.14 (m, 2H, cyclohexyl), 
1.16-1.36 (m, 3H, cyclohexyl), 1.65-1.79 (m, 3H, cyclohexyl), 1.80-1.92 (m, 3H, cyclohexyl), 2.52 
(s, 3H, Ar-CH3), 4.28 (d, 2H, J = 6.4 Hz, OCH2), 6.32 (s, 2H, NH2), 7.37 (dd, 1H, J = 7.4, 7.5 Hz, 
H-5), 7.43 (d, 1H, J = 7.4 Hz, H-4), 7.52 (s, 1H, NH), 7.63 (d, 1H, J = 7.5 Hz, H-6), 7.88 (s, 1H, 
NH), 12.67 (s, 1H, NH); 13C NMR (d6-DMSO, 125 MHz)  17.5, 26.8, 27.5, 30.8, 38.7, 72.8, 
126.9, 129.5, 132.4, 132.6, 135.7, 139.7, 161.6, 175.2; HRMS [M+H]+ (C20H25N6O2) calcd 
381.2034, obsd 381.2030. 
3-(2-Amino-6-(cyclohexylmethoxy)-9H-purin-8-yl)benzenesulfonamide (44). In accordance with 
Method IV from 41 (29 mg; 0.045 mmol) and TFA (1 mL) (3h at 20 °C). Purification by 
chromatography on silica, employing a gradient elution of EtOAc:Petrol (4:1) to 100% EtOAc, 
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furnished the title compound as a white solid (11 mg; 61%); mp 159-162 °C; IR 3323, 2920, 2851, 
1651, 1625, 1530 cm-1; 1H NMR (MeOD-d4, 500 MHz,)  1.09-1.20 (2H, m, cyclohexyl), 1.24-1.40 
(3H, m, cyclohexyl), 1.68-1.84 (3H, m, cyclohexyl), 1.90-1.97 (3H, m, cyclohexyl), 4.33 (2H, d, J = 
6.2 Hz, OCH2), 7.68 (1H, dd, J = 7.8, 7.9 Hz, H-5), 7.99 (1H, d, J = 7.8 Hz, H-4), 8.22 (1H, d, J = 
7.9 Hz, H-6), 8.58 (1H, s, H-2); 13C NMR (MeOD-d4, 125 MHz) 26.9, 27.57,30.81, 38.78, 73.0, 
125.21, 128.4, 130.75, 130.88, 131.8, 146.22, 161.61; HRMS [M+H]+ (C18H23N6O3S) calcd 
403.1547, obsd 403.1546. 
3-(2-Amino-6-(cyclohexylmethoxy)-9H-purin-8-yl)-2-methylbenzenesulfonamide (45). 
Prepared in accordance with Method IV from 42 (60 mg; 0.092 mmol) and TFA (1 mL) (90 min at 
80 °C. Isolated by chromatography on silica, using a gradient elution of 100% EtOAc to EtOAc: 
MeOH (5:1), to give the title compound as a white powder (30 mg; 78%); mp 258-259 °C;IR 3503, 
3407, 2927, 2851, 1629, 1587 cm-1; 1H NMR (d6-DMSO, 500 MHz)  0.94-1.10 (2H, m, 
cyclohexyl), 1.15-1.33 (3H, m, cyclohexyl), 1.61-1.75 (3H, m, cyclohexyl),1.77-1.86 (3H, m, 
cyclohexyl), 2.68 (3H, s, Ar-CH3), 4.24 (2H, d, J = 6.3 Hz, OCH2), 6.32 (2H, s, NH2), 7.49 (1H, dd, 
J = 7.6, 7.8.Hz, H-5), 7.55 (2H, s, NH2), 7.73 (1H, d, J = 7.6 Hz, H-4), 8.00 (1H, d, J = 7.8 Hz, H-
6), 12.70 (1H, s, NH); 13C NMR (d6-DMSO, 125 MHz)  17.0, 25.2, 26.0, 29.2, 36.8, 70.6, 125.7, 
143.4, 159.7, 160.3; HRMS [M+H]+ (C19H25N6O3S) calcd 417.1703, obsd 417.1697. 
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Crystallography 
Crystals of monomeric CDK2 (kindly supplied by C.A. Minshull, AstraZeneca, Macclesfield, UK) 
were soaked for 24 h in a 5 mM solution of compound 26 in mother liquor (50 mM ammonium 
acetate, 10% PEG-3350, 15 mM NaCl, 100 mM HEPES, pH = 7.4, 10% DMSO). The crystals were 
cryo-protected in 50 mM ammonium acetate, 10% PEG-3350, 25% glycerol, 100 mM HEPES, pH 
7.4 and mounted into a 100 K nitrogen stream. Data collection was carried out at AstraZeneca, 
Macclesfield, UK, using a Bruker-Nonius FR591 rotating anode generator and an XrayResearch 
Mar345 image plate. Compounds 29, 32, 36, 37, 44, and 45 were co-crystallised with CDK2/cyclin 
A as previously described.20 Before data collection, crystals were briefly immersed in cryo-
protectant (8 M sodium formate) before freezing. 
Data processing was carried out using MOSFLM,38 SCALA39 and other programs of the CCP4 
suite.40 The structures of CDK2/compound 26 and of compounds 29, 32, 36 and 37 bound to 
CDK2/cyclin A were solved by molecular replacement using MOLREP41 taking, respectively, the 
protein atoms of an unpublished structure of CDK2 bound to a derivative of 5, or CDK2/cyclin A/7 
(PDB accession code 1H1S,22) as the search model. Structures of 44 and 45 bound to CDK2/cyclin 
A were solved by Phaser,42 using as the search model a high-resolution structure of a recruitment 
peptide bound to CDK2/cyclin A (PDB accession code 2CCH). Each solution was then subjected to 
rigid body refinement in REFMAC,43 revealing unambiguous electron density in the CDK2 ATP-
binding site, consistent with the expected shapes of the inhibitors. Models of 26, 29, 32, 36 and 37 
were created using the CCP4 Sketcher,40 and manually docked into the density using either O43 
(compounds 26 and 29) or Coot45 (compounds 32, 36 and 37). Models of 44 and 45 were created 
using the Elbow Builder utility, and built into the electron density using Coot. The inhibitor atoms 
were kept in all subsequent models during refinement. The structures were then refined further by 
rounds of manual rebuilding in O (for compounds 26 and 29) or in Coot (compounds 32, 36, 37, 44 
and 45) and restrained refinement in REFMAC. Towards the end of refinement, waters were added 
using ARP/wARP,46 (compounds 26 and 29) or the Coot water picking utility (32, 36, 37, 44 and 
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45) and manually verified. The statistics for the datasets and for the crystallographic refinement are 
presented in Table S1.  The structures of CDK2/compound 26, and compounds 32, 29, 36 37, 44 
and 45 bound to CDK2/cyclin A have been deposited in the PDB with accession codes 1W8C, 
4CFN, 4CFM, 4CFV, 4CFU, 4CFX and 4CFW respectively.  
Modelling 
The refined structure of mCDK2/compound 26 was aligned with CDK2/inhibitor structures using 
LSQKAB.47 The kinases were aligned based on the alpha carbon positions of the residues Glu81, 
Phe82, Leu83, His84, Gln85 and Ala31.  The hinge residues (Glu81-Gln85) were used as all the 
inhibitors investigated form hydrogen bonds with the backbone atoms in this region.  Ala31 was 
used to allow the reliable alignment of the monomeric and the cyclin-bound CDK2 structures.48  
Conformation-energy profiles were calculated with Gaussian.47 Models were created using the 
CCP4 monomer sketcher40 and InsightII (Accelrys, CA, USA), and then converted into Z matrices. 
The purine and aryl rings were constrained to co-planarity, and the models energy minimised with 
the 6-31G** basis set. Rigid potential energy scans were carried out at 5 intervals between the two 
co-planar conformations using the 3-21G basis set. 
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